LGC Clinical Diagnostics’ Post

New Product Announcement! We’re excited to introduce the Seraseq Solid Tumor FFPE DNA Reference Material, designed to address the challenges of #FFPE tissue samples in #GenomicProfiling. This material includes 74 biosynthetic DNA variants across 62 solid tumor-associated genes, featuring 37 SNVs, 18 deletions, 5 insertions, and 10 translocations. 65 of these variants are linked to FDA drug targets, offering a robust benchmark for clinical relevance. The material is provided in a lightly fixed FFPE format with clinically relevant allelic frequencies, ideal for testing assay sensitivity and detection limits. Learn more and access the complete table of mutations here: https://hubs.ly/Q02-rxx50 #CancerDiagnostics #DNASequencing #ClinicalGenomics #AssayDevelopment #CancerResearch

Sotorasib, also known as also known as AMG-510, is a potent KRAS G12C covalent inhibitor and the active atropisomer separated by chiral HPLC. Thanks for the success of process chemistry, we are now able to offer big discount for bulk quantity. For detail, please visit our web page: https://lnkd.in/eGcC3hx. AMG-510 selectively targets the KRAS p.G12C mutant, at either the DNA, RNA or protein level, and prevents, through an as of yet not elucidated manner, expression of and/or tumor cell signaling through the KRAS p.G12C mutant. This may inhibit growth in KRAS p.G12C-expressing tumor cells. Note: According to Sci-Finder database, CAS#2252403-56-6 is a AMG510 active atropisomer. Many vendor mistakenly listed CAS#2296729-00-3 as the AMG510 active atropisomer.

Read Here: https://hubs.li/Q02XqBrM0 KIF18A is critical in cell division, and inhibiting it presents a promising approach for cancers with chromosomal instability (CIN) or whole-genome duplication (WGD), such as ovarian and breast cancers. However, challenges like the shallow allosteric binding site and limited structural data make designing potent and safer inhibitors difficult. Our Approach: We utilized XPose, our proprietary simulation model, to gain structural insights and guide the virtual screening of AI-generated compounds. With scaffold hopping, we designed novel compounds targeting key pharmacophores. Key Outcomes: ▪️ XPose and XFEP enabled rational drug design and affinity prediction, streamlining preclinical candidate nomination. ▪️ Advanced from Lead-ID to the preclinical non-GLP tox study stage, synthesizing just 120 compounds. ▪️ Nominated XTN187 as a potential best-in-class oral agent with improved safety and efficacy in CDX models at comparable dosages to Sovilnesib. #drugdiscovery #cancertreatment #preclinicalcandidate

A Next-Generation, Mutant-Selective PI3Kα Allosteric Inhibitor from Scorpion Tx with a Potentially Improved Safety Profile | https://lnkd.in/grrEWg7b STX-478 is an oral, CNS-penetrant, WT-sparing allosteric inhibitor of mutant PI3Kα, a key player in many cancers. The selectivity profile of this compound may be a key differentiator in the clinic by avoiding the metabolic dysfunction seen in current generation pan-PI3Kα inhibitors. Scorpion Therapeutics recently highlighted promising efficacy and safety data for STX-478 in their ESMO 2024 presentation, including key hyperglycemia data which we’ve covered in this updated article! This full case study explores the discovery and lead optimization of STX-478, its pharmacology, preclinical and clinical data, and how it compares to other PI3Kα inhibitors in the field. Read it on Drug Hunter | https://lnkd.in/grrEWg7b

Missed our presentations at AACR? Don't worry! Check out our recap on one of our most popular posters: A WRN Screening Cascade to Facilitate Novel Drug Discovery. Key Highlights: ▶ WRN Functions: Involved in DNA replication, repair, recombination, transcription, and telomere stabilization. ▶ Innovative Screening Cascade: Integrated in vitro and in vivo assays for high throughput screening. ▶ Tools & Models: Purified WRN proteins, WRN knock-out and WRN-HiBiT knock-in cell lines, and multiple CDX models. Learn more and download the poster here: https://lnkd.in/gAyFbfm5 #ICEBioscience #AACR #DrugDiscovery #WRN #Biotechnology #CancerResearch #CDX #knockout #knockin #HTS

🔬 QIAGEN Q2 Earnings Beat Estimates! 📊 Key Highlights: -Revenue: $496.3M, slightly up from $494.9M last year, beating estimates. -Segments: Diagnostics up 5%, PCR and nucleic acid amplification up 2%, -Genomics and NGS down 9%. -Net Loss: $183.5M ($.83/share) vs. net income of $80.8M ($.35/share) last year. -Adjusted EPS: $.55, beating expectations of $.51. Notable Achievements: -Launched 35 new dPCR assays and QIAseq Multimodal DNA/RNA Library Kit. -Partnered with the FBI for QiAcuity dPCR assay. -Therascreen KRAS RGQ PCR Kit cleared by FDA for colorectal cancer treatment. Outlook: Q3 2024: Expected sales of at least $495M, adjusted EPS of at least $.55. Full-year 2024: Sales forecast at $1.99B, EPS raised to $2.16. "We are on track to achieve our updated outlook reflecting strong core business trends," said CEO Thierry BERNARD. #Qiagen #Q2Results #Diagnostics #MedicalResearch #Biotech #InvestorUpdate

The U.S. Food and Drug Administration approved Tecelra (afamitresgene autoleucel) for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA antigen(s) A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive, and whose tumor expresses the MAGE-A4 antigen. GTC's Solid tumor Profile-Plus provides comprehensive evaluation of fusions (including SS18::SSX), MAGE-A4 RNA expression, and HLA genotyping (including A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P) in one assay with a 5-10 day TAT Do not accept partial results and order the Solid Tumor Profile Plus Learn more: https://lnkd.in/d8NzX7b #Synovialsarcoma #MAGE-A4 #RNA

An Allosteric Pan-Mutant-Selective PI3Kα Inhibitor Without Hyperglycemia in Preclinical Models | https://lnkd.in/gu9AyiXH RLY-2608 is an oral, mutant-selective PI3Kα allosteric inhibitor from Relay Therapeutics, targeting a cryptic pocket near the ATP-binding site. Given the challenges and toxicities associated with WT PI3Kα inhibition—such as hyperglycemia and rash—there's an increasing need for next-generation, mutant-selective PI3Kα inhibitors. Relay Therapeutics recently shared promising interim data from the Phase I ReDiscover trial in patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer. Explore this case study on RLY-2608 to dive into the discovery strategy, mechanisms driving mutant selectivity, its position in the competitive landscape, preclinical activity, recent clinical developments, and more. Full Article: https://lnkd.in/gu9AyiXH

🌟 Introduction to AnuBio AnuBio is a closed-loop, lab-AI immunotherapeutic drug discovery company dedicated to discovering novel bispecific biologics to enhance the robustness of immune responses. Our proprietary PHENOMS and TRAILBLAZER platforms work synergistically to decode the native language of the immune system. The PHENOMS platform is the largest combinatorial signaling screening platform, capable of testing millions of immune "sentences," while TRAILBLAZER is a custom-built, large cellular language model designed to understand and translate the results into human efficacy. Together, they create solutions to previously untraceable problems, offering hope for a world free of cancer and autoimmune diseases.

DPYD variants contribute to severe or even fatal toxicity in up to 40% of cancer patients treated with 5-FU and capecitabine*. Don't leave your testing to chance—validate and assess your DPYD molecular assay with our latest reference material - Seraseq® DPYD DNA Mutation Mix and enhance patient safety. Highly multiplexed, 39 pathogenic mutations, 1 vial. Precision diagnostics save lives! Find out more: https://hubs.ly/Q02Q9p3t0 #ClinicalDiagnostics #Pharmacogenomics #PrecisionMedicine #DPYD #Seraseq #QualityControl #ReferenceMaterial #Accuracy *Source: Amstutz, U., et al. (2018): "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update." Clinical Pharmacology & Therapeutics, 103(2), 210-216.